Market Research Logo

Ischemia Reperfusion Injury - Pipeline Review, H2 2016

Introduction
Global Markets Direct Report Coverage
Ischemia Reperfusion Injury Overview
Therapeutics Development
Pipeline Products for Ischemia Reperfusion Injury - Overview
Pipeline Products for Ischemia Reperfusion Injury - Comparative Analysis
Ischemia Reperfusion Injury - Therapeutics under Development by Companies
Ischemia Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes
Ischemia Reperfusion Injury - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Ischemia Reperfusion Injury - Products under Development by Companies
Ischemia Reperfusion Injury - Products under Investigation by Universities/Institutes
Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development
Amyndas Pharmaceuticals LLC
Angion Biomedica Corp.
Biomedica Management Corporation
Bolder Biotechnology, Inc.
Corline Biomedical AB
Curatis Pharma GmbH
Erimos Pharmaceuticals, LLC
Gilead Sciences, Inc.
Ischemix, Inc.
Kowa Company, Ltd.
LG Life Science LTD.
Omeros Corporation
Opsona Therapeutics Limited
Orexo AB
Pharming Group N.V.
PledPharma AB
Prolong Pharmaceuticals, LLC
Proteo, Inc.
Prothix BV
Recordati S.p.A.
Stealth BioTherapeutics Inc.
Ischemia Reperfusion Injury - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AER-271 - Drug Profile
AM/AMBP-1 - Drug Profile
ANV-6L15 - Drug Profile
APP-103 - Drug Profile
BB-3 - Drug Profile
BBT-059 - Drug Profile
C1 esterase inhibitor (recombinant) - Drug Profile
CMX-2043 - Drug Profile
CRX-526 - Drug Profile
Curaglutide - Drug Profile
Des-Asp Angiotensin 1 - Drug Profile
Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drug Profile
elamipretide - Drug Profile
EP-80317 - Drug Profile
GS-459679 - Drug Profile
hemin (human) - Drug Profile
KN-93 - Drug Profile
LH-021 - Drug Profile
mangafodipir trisodium - Drug Profile
MG-53 - Drug Profile
mirococept - Drug Profile
Monoclonal Antibodies to Inhibit MMP-8 for Renal Ischemia and Shock - Drug Profile
Monoclonal Antibody for Ischemia Reperfusion Injury - Drug Profile
Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease and Kidney Transplantation - Drug Profile
Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury - Drug Profile
NecX - Drug Profile
Neutrolide - Drug Profile
NP-202 - Drug Profile
Oligonucleotide for Oncology and Cardiovascular Diseases - Drug Profile
OMS-721 - Drug Profile
OPN-305 - Drug Profile
pitavastatin NP - Drug Profile
PRO-02 - Drug Profile
R-190 - Drug Profile
Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischemia - Drug Profile
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile
Recombinant Protein Slit2 to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile
Recombinant Protein to Antagonize EPHA4 for ALS, Acute Spinal Cord Injury and Ischemia Reperfusion Injury - Drug Profile
Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile
Recombinant Proteins to Agonize PTCH1 for Ischemia Reperfusion Injury - Drug Profile
Recombinat Protein to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile
Renaparin - Drug Profile
Sanguinate - Drug Profile
Small Molecule to Agonize Adenosine Receptor for Neurodegenerative Diseases and Ischemia Reperfusion Injury - Drug Profile
Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile
Small Molecules for Ischemia Reperfusion Injury - Drug Profile
Small Molecules for Ischemia Reperfusion Injury - Drug Profile
Small Molecules for Ischemia Reperfusion Injury - Drug Profile
Small Molecules for Ischemia Reperfusion Injury and Inflammation - Drug Profile
Small Molecules to Activate Protein Kinase B for Ischemia Reperfusion Injury - Drug Profile
Small Molecules to Activate SGK-1 for Ischemic Reperfusion Injury - Drug Profile
Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile
Synthetic Peptides for Ischemia Reperfusion Injury - Drug Profile
Synthetic Peptides for Oncology, Immunology and Cardiovascular Disorders - Drug Profile
terameprocol - Drug Profile
tiprelestat - Drug Profile
TMS-007 - Drug Profile
UCF-101 - Drug Profile
UWA-TAT - Drug Profile
VCP-746 - Drug Profile
Ischemia Reperfusion Injury - Dormant Projects
Ischemia Reperfusion Injury - Discontinued Products
Ischemia Reperfusion Injury - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Ischemia Reperfusion Injury, H2 2016
Number of Products under Development for Ischemia Reperfusion Injury - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Ischemia Reperfusion Injury - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016
Ischemia Reperfusion Injury - Pipeline by Angion Biomedica Corp., H2 2016
Ischemia Reperfusion Injury - Pipeline by Biomedica Management Corporation, H2 2016
Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology, Inc., H2 2016
Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, H2 2016
Ischemia Reperfusion Injury - Pipeline by Curatis Pharma GmbH, H2 2016
Ischemia Reperfusion Injury - Pipeline by Erimos Pharmaceuticals, LLC, H2 2016
Ischemia Reperfusion Injury - Pipeline by Gilead Sciences, Inc., H2 2016
Ischemia Reperfusion Injury - Pipeline by Ischemix, Inc., H2 2016
Ischemia Reperfusion Injury - Pipeline by Kowa Company, Ltd., H2 2016
Ischemia Reperfusion Injury - Pipeline by LG Life Science LTD., H2 2016
Ischemia Reperfusion Injury - Pipeline by Omeros Corporation, H2 2016
Ischemia Reperfusion Injury - Pipeline by Opsona Therapeutics Limited, H2 2016
Ischemia Reperfusion Injury - Pipeline by Orexo AB, H2 2016
Ischemia Reperfusion Injury - Pipeline by Pharming Group N.V., H2 2016
Ischemia Reperfusion Injury - Pipeline by PledPharma AB, H2 2016
Ischemia Reperfusion Injury - Pipeline by Prolong Pharmaceuticals, LLC, H2 2016
Ischemia Reperfusion Injury - Pipeline by Proteo, Inc., H2 2016
Ischemia Reperfusion Injury - Pipeline by Prothix BV, H2 2016
Ischemia Reperfusion Injury - Pipeline by Recordati S.p.A., H2 2016
Ischemia Reperfusion Injury - Pipeline by Stealth BioTherapeutics Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Ischemia Reperfusion Injury - Dormant Projects, H2 2016
Ischemia Reperfusion Injury - Dormant Projects (Contd..1), H2 2016
Ischemia Reperfusion Injury - Dormant Projects (Contd..2), H2 2016
Ischemia Reperfusion Injury - Dormant Projects (Contd..3), H2 2016
Ischemia Reperfusion Injury - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Ischemia Reperfusion Injury, H2 2016
Number of Products under Development for Ischemia Reperfusion Injury - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

Ischemia Reperfusion Injury - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Ischemia Reperfusion Injury - Pipeline Review, H2 2016’, provides an overview of the Ischemia Reperfusion Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury
  • The report reviews pipeline therapeutics for Ischemia Reperfusion Injury by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Ischemia Reperfusion Injury therapeutics and enlists all their major and minor projects
  • The report assesses Ischemia Reperfusion Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;